VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALXO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALXOALX Oncology Holdings Inc.
$0.97$131M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ALXO
  4. Financial Ratios

ALX Oncology Holdings Inc. (ALXO) Financial Ratios

Latest Ratios: P/E Ratio -1.7x · EV/EBITDA N/A · ROE -145.7%. (2018–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ALXO Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$131M$61M$87M$640M$459M$866M$3.4B——
Enterprise Value$119M$49M$87M$635M$420M$503M$3.0B——
P/E Ratio →-1.70————————
P/S Ratio——————2905.75——
P/B Ratio2.002.330.773.371.742.397.99——
P/FCF—————————
P/OCF—————————

P/E links to full P/E history page with 30-year chart

ALXO EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue——————2538.39——
EV / EBITDA—————————
EV / EBIT—————————
EV / FCF—————————

ALXO Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin——————9.1%9.1%9.0%
Operating Margin——————-3694.0%-400.0%-662.0%
Net Profit Margin——————-3869.7%-401.2%-664.3%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE-145.7%-145.7%-88.9%-71.0%-39.4%-21.1%-21.3%-433.4%-150.0%
ROA-98.3%-98.3%-69.1%-58.6%-36.0%-20.5%-20.5%-176.2%-123.0%
ROIC-122.0%-122.0%-71.8%-62.4%-84.9%-50537.3%——-1149.3%
ROCE-127.0%-127.0%-84.8%-70.3%-39.6%-21.0%-20.1%-256.1%-147.3%

ALXO Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.200.200.150.090.040.00———
Debt / EBITDA—————————
Net Debt / Equity—-0.43-0.01-0.03-0.15-1.00-1.01—-0.90
Net Debt / EBITDA—————————
Debt / FCF—————————
Interest Coverage-62.48-62.48-76.99-101.75-517.56-6420.85-53.84-913.71—

Net cash position: cash ($16M) exceeds total debt ($5M)

ALXO Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio2.072.077.265.249.5724.0070.281.975.45
Quick Ratio2.072.077.265.249.5724.0070.281.975.45
Cash Ratio1.821.826.915.089.4023.7869.991.814.41
Asset Turnover——————0.000.450.19
Inventory Turnover—————————
Days Sales Outstanding———————40.79164.58

ALXO Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield—————————
Payout Ratio—————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield—————————
FCF Yield—————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$54M$52M$43M$41M$40M$40M$22M$22M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Dependence on external equity funding

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Book Value Premium Despite Losses

ALXO trades at a P/B of 2.40 with a P/E of -0.61 as reported, implying the market prices the pipeline well above the reported equity base despite a cumulative operating loss exceeding $200M over the period shown.

A negative P/E is not meaningful for valuation, so the 2.40 price-to-book multiple is the more informative anchor here. It suggests investors are assigning value to clinical assets and optionality that do not appear on the balance sheet, which warrants further investigation into the pipeline's probability of success. Without forward estimates or EV-based multiples, a relative valuation against own history or peers is limited by the absence of comparable earnings or EBITDA.

Persistently Negative Returns Narrowing

Based on ALXO's reported figures, ROIC improved from -26.0% in 2025Q1 to -10.9% in 2026Q2, though returns remained deeply negative across all ten quarters shown, peaking at -85.2% in 2025Q4.

The trajectory reflects a shrinking loss base rather than any improvement in capital productivity, since the company generates no reported revenue to earn a return on. The sharp deterioration in 2025Q4, when ROE fell to -64.6%, appears linked to a contraction in equity rather than a change in operating economics. Investors should monitor whether returns stabilize as the equity base is rebuilt through issuance.

Low Debt Masks Equity Dependence

As reported in financial statements, ALXO's debt-to-equity ratio sits at 0.07 in 2026Q2 with interest coverage of -63.27, reflecting negative operating earnings rather than any meaningful debt service burden.

The low leverage ratio suggests the company is funded almost entirely by equity, so the absence of debt pressure should not be read as financial strength. Interest coverage is negative because operating income is negative, which means the coverage metric carries little diagnostic value here. The more relevant risk is the recurring need to raise equity to fund operations.

Liquidity Ratios Mask Thin Runway

Based on reported figures, ALXO's current ratio of 9.71 in 2026Q2 appears strong, yet cash of $22.7M against free cash flow of roughly -$34.8M suggests the liquidity cushion covers less than one quarter of burn.

The elevated current ratio is driven by the composition of current assets and does not capture the pace of cash consumption. Against quarterly cash outflows of this magnitude, the liquidity position appears highly dependent on near-term capital raises. Under a severe stress scenario where equity markets close, the current ratio offers little reassurance about operational continuity.

P/B Overstates Asset Backing

The most commonly misapplied metric for a pre-revenue biotech is the price-to-book ratio, which may look like asset coverage but reflects capitalized equity raised rather than tangible earning assets.

For a clinical-stage company, book value largely reflects cash contributed by shareholders and is being consumed by R&D spending, so a 2.40 P/B does not indicate downside protection. A more useful alternative is cash runway measured against projected burn, combined with the probability-weighted value of the pipeline. Investors should treat P/B as a measure of market-assigned optionality rather than asset security.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus & Technical Research Suite
Open ALXO Terminal

ALXO Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ALXO — Frequently Asked Questions

Quick answers to the most common questions about buying ALXO stock.

What is ALX Oncology Holdings Inc.'s P/E ratio?

ALX Oncology Holdings Inc.'s current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.

What is ALX Oncology Holdings Inc.'s ROE?

ALX Oncology Holdings Inc.'s return on equity (ROE) is -145.7%. The historical average is -121.3%.

Is ALXO stock overvalued?

Based on historical data, ALX Oncology Holdings Inc. is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.